Product Description
St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Russia
Approved Indications: None
Known Adverse Events: None
Company: City of Hope Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|